Proprietary Database, Market Surveys, Strategic Consultation & Advisory Services, Industry & Competitive Intelligence — Revenue, Volume, Production, Trade Analysis, Market Size, Share, Forecast, Drivers, Trends, Growth Opportunities, ESG and more.
| Data Timeline | Historical Data: 2022–2025 | Base Year: 2025 | Forecast Period: 2026–2034 |
|---|---|
| Type Segment | ED Drugs, ED Devices |
| Application Segment | Congenital Patients, Pathological Patients |
| End User Segment | Hospitals and ASCs, Clinics |
|---|---|
| Distribution Channel Segment | Retail Pharmacies, Hospital Pharmacies, Online Portals |
| Regions & Countries |
|
Country-level data · Company profiles · Editable dataset · Analyst consultation included.
| Region / Country | 2021 (A) | 2025 (A) | 2033 (P) | CAGR |
|---|
A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.
Unlock full regional dataset →Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.
To learn more about market share and segmentation, request the free sample pages.
The competitive landscape of the erectile dysfunction (ED) market is characterized by intense competition among pharmaceutical companies and medical device manufacturers striving to gain a competitive edge through product innovation, strategic partnerships, and marketing strategies.
In September 2022, Advanced MedTech Holdings (Singapore) acquired Shenzhen Huikang Medical Apparatus Co., Ltd. (China). This acquisition expanded Advanced MedTech's urological market access in China via comprehensive nationwide sales and service network and an established local R&D, manufacturing, and supply chain ecosystem.
In April 2022, Wikkon's extracorporeal shock wave lithotripter, model HK.ESWL-108A was successfully installed at Maria Clinic, Dili, and East Timor.
(Source: https://eswl.com/wikkons-first-eswl-installation-in-east-timor/)
| Company | 2022 (A) | 2023 (A) | 2024 (A) | 2025 (A) |
|---|---|---|---|---|
| Coloplast | ••• | ••• | ••• | ••• |
| Boston Scientific | ••• | ••• | ••• | ••• |
| Pfizer | ••• | ••• | ••• | ••• |
| Eli Lilly and Company | ••• | ••• | ••• | ••• |
| Teva Pharmaceuticals | ••• | ••• | ••• | ••• |
| Bayer | ••• | ••• | ••• | ••• |
Revenue data requires full access. *2nd & 3rd tier companies available on enquiry.
Request company profile for validation →According to Cognitive Market Research, the global Erectile Dysfunction market size is USD 4681.2million in 2024 andwill expand at a compound annual growth rate (CAGR) of 8.00% from 2024 to 2031.
The Erectile Dysfunction (ED) market refers to the pharmaceutical and medical devices sector focused on addressing difficulties in achieving or maintaining penile erection sufficient for sexual intercourse. ED is a common condition affecting men of various ages and can arise from a multitude of factors, including underlying health conditions like diabetes, cardiovascular diseases, hormonal imbalances, psychological factors such as stress or anxiety, and lifestyle choices like smoking or excessive alcohol consumption. One of the key drivers in the erectile dysfunction market is the aging population. As individuals age, they are more likely to experience health conditions that contribute to erectile dysfunction, such as diabetes, hypertension, and cardiovascular diseases. Consequently, the growing elderly population worldwide is fuelling the demand for ED treatments. Additionally, advancements in medical technology and treatment modalities have led to the development of more effective and less invasive solutions for erectile dysfunction.
Another significant driver in the erectile dysfunction market is the increasing awareness and destigmatization of the condition. As societal attitudes toward sexual health evolve and awareness campaigns raise visibility, more men are seeking help for erectile dysfunction without feeling ashamed or embarrassed.
In June 2023, Rigicon, Inc. (US) introduced the HL-LEVINE Combo Prosthesis Tool, which is a combination of the HL dilator tool and the traditional Furlow instrument, which are both used for penile implant surgery.
★ Reviews
Rate this report
| Type | ED Drugs, ED Devices |
| Application | Congenital Patients, Pathological Patients |
| End User | Hospitals and ASCs, Clinics |
| Distribution Channel | Retail Pharmacies, Hospital Pharmacies, Online Portals |
| List of Competitors | Coloplast, Boston Scientific, Pfizer, Eli Lilly and Company, Teva Pharmaceuticals, Bayer |
Global Market has been segmented on the basis 5 major regions such as North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
You can purchase only the Executive Summary of Global Market (2019 vs 2024 vs 2031)
Global Market Dynamics, Trends, Drivers, Restraints, Opportunities, Only Pointers will be deliverable
(Subject to Data Availability (Private Players))
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Data Subject to Availability as we consider Top competitors and their market share will be delivered.
Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.
Cognitive Market Research employs "The Full Truth™" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Global Erectile Dysfunction Market Analysis Market analysis.
Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.
Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.
Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.
Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.
Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.
To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.
We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Global Erectile Dysfunction Market Analysis market.
Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the global erectile dysfunction market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.
Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.
Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.
Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.